Department of Physiology, Faculty of Medicine, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.
Department of Basic Medical Sciences, Faculty of Dentistry, University of Debrecen, 98 Nagyerdei krt, 4032 Debrecen, Hungary.
Int J Mol Sci. 2022 Apr 18;23(8):4435. doi: 10.3390/ijms23084435.
Cardiac diseases are the leading causes of death, with a growing number of cases worldwide, posing a challenge for both healthcare and research. Therefore, the most relevant aim of cardiac research is to unravel the molecular pathomechanisms and identify new therapeutic targets. Cardiac ryanodine receptor (RyR2), the Ca release channel of the sarcoplasmic reticulum, is believed to be a good therapeutic target in a group of certain heart diseases, collectively called cardiac ryanopathies. Ryanopathies are associated with the impaired function of the RyR, leading to heart diseases such as congestive heart failure (CHF), catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmogenic right ventricular dysplasia type 2 (ARVD2), and calcium release deficiency syndrome (CRDS). The aim of the current review is to provide a short insight into the pathological mechanisms of ryanopathies and discuss the pharmacological approaches targeting RyR2.
心脏病是全球死亡的主要原因之一，病例数量不断增加，对医疗保健和研究都构成了挑战。因此，心脏研究的最相关目标是揭示分子病理机制并确定新的治疗靶点。心肌兰尼碱受体（RyR2）是肌浆网的 Ca 释放通道，被认为是一组特定心脏病（统称为心肌病变）的良好治疗靶点。心肌病变与 RyR 功能障碍有关，导致心力衰竭（CHF）、儿茶酚胺多形性室性心动过速（CPVT）、心律失常性右室发育不良 2 型（ARVD2）和钙释放缺陷综合征（CRDS）等疾病。本综述的目的是简要探讨心肌病变的病理机制，并讨论针对 RyR2 的药理学方法。
